Visible Genetics, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Maker and marketer of automated DNA sequencing systems plans to file in the third quarter a 510(k) with FDA for market clearance of its Trugene HIV-1 genotyping assay. In December, FDA had said the firm did not need to complete a clinical trial for inclusion in a premarket approval application, but that proficiency trials should be completed. Separately, second quarter financial results announced Aug. 17 included sales of $3.4 mil. (up 78.9%). A net loss of $8.6 mil. compares to a net loss of $7.1 mil. for the same quarter last year
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.